WuXi XDC Cayman (HKSE:02268) Gross-Profit-to-Asset % : 16.32% (As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is WuXi XDC Cayman Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. WuXi XDC Cayman's annualized Gross Profit for the quarter that ended in Jun. 2023 was HK$486 Mil. WuXi XDC Cayman's average Total Assets over the quarter that ended in Jun. 2023 was HK$2,976 Mil. Therefore, WuXi XDC Cayman's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 was 16.32%.

WuXi XDC Cayman Gross-Profit-to-Asset % Historical Data

The historical data trend for WuXi XDC Cayman's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi XDC Cayman Gross-Profit-to-Asset % Chart

WuXi XDC Cayman Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

1.98

17.80

15.09

12.05

WuXi XDC Cayman Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial			-	-	18.78	16.32	-

Competitive Comparison of WuXi XDC Cayman's Gross-Profit-to-Asset %

For the Diagnostics & Research subindustry, WuXi XDC Cayman's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

WuXi XDC Cayman's Gross-Profit-to-Asset % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where WuXi XDC Cayman's Gross-Profit-to-Asset % falls into.

WuXi XDC Cayman Gross-Profit-to-Asset % Calculation

WuXi XDC Cayman's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	612.033	/	( (2787.743	+	7366.952)	/ 2 )
	=	612.033	/	5077.3475
	=	12.05 %

WuXi XDC Cayman's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Jun. 2023 )	/	( (Total Assets (Q: Mar. 2023 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
	=	485.748	/	( (2955.832	+	2996.904)	/ 2 )
	=	485.748	/	2976.368
	=	16.32 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Jun. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

WuXi XDC Cayman Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of WuXi XDC Cayman's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi XDC Cayman (HKSE:02268) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi XDC Cayman Inc (HKSE:02268) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

L74:Germany

Address

No. 11 Xinhui Ring Road, Xinwu, Jiangsu, Wuxi, CHN

Website

WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.

WuXi XDC Cayman (HKSE:02268) Headlines

No Headlines